FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to a pharmaceutical composition containing neoantigen peptide for use in the treatment of mammary gland cancer. The obtained pharmaceutical composition contains neoantigen peptide containing tumor-specific neoepitope containing one or several adjacent mutant amino acids encoded by a sequence obtained by a mutation of a reading frame shift in GATA3 gene, where tumor-specific neoepitope is encoded by GATA3 gene of subject’s cancer cells or expressed by subject’s cancer cells.
EFFECT: invention can be used for the effective treatment of mammary gland cancer.
23 cl, 9 dwg, 3 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEOANTIGENS AND THEIR APPLICATION | 2019 |
|
RU2805196C2 |
| NEOANTIGENS AND THEIR USE | 2019 |
|
RU2813924C2 |
| ANTIBODIES THAT BIND TUMOR TISSUE FOR DIAGNOSIS AND TREATMENT | 2020 |
|
RU2806915C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETED TO FC RECEPTOR-LIKE PROTEIN 5, AND THEIR USE | 2015 |
|
RU2779747C2 |
| CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
| ANTIBODIES SPECIFIC FOR CD70 AND THEIR USE | 2019 |
|
RU2801093C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| POLY-SPECIFIC BINDING PROTEINS TARGETED TO CAIX, ANO1, MESOTHELIN, TROP2, CEA, AND CLAUDINE-18.2 | 2018 |
|
RU2792671C2 |
| POLYSPECIFIC BINDING PROTEINS TARGETING NKG2D, CD16 AND TROP2 | 2018 |
|
RU2820629C2 |
| CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS TARGETING DLL3 | 2020 |
|
RU2822366C2 |
